HEPARIN SODIUM IN 0.9% SODIUM CHLORIDE INJECTION 430 MG / 100 ML — DIN 01935933
SODIUM PHOSPHATE DIBASIC : 430 MG / 100 ML CITRIC ACID : 37 MG / 100 ML SODIUM CHLORIDE : 900 MG / 100 ML HEPARIN SODIUM : 200 UNIT / 100 ML · B. BRAUN MEDICAL INC · SOLUTION · wholesale supply in Canada
Health Canada status: DORMANT
What is HEPARIN SODIUM IN 0.9% SODIUM CHLORIDE INJECTION?
HEPARIN SODIUM IN 0.9% SODIUM CHLORIDE INJECTION 430 MG / 100 ML contains SODIUM PHOSPHATE DIBASIC : 430 MG / 100 ML CITRIC ACID : 37 MG / 100 ML SODIUM CHLORIDE : 900 MG / 100 ML HEPARIN SODIUM : 200 UNIT / 100 ML. It is listed in the Health Canada Drug Product Database under DIN 01935933, held by B. BRAUN MEDICAL INC, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as dormant, status dated 14-Jul-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A). This DIN is not currently being marketed in Canada, so it is sourced to order where a compliant route exists rather than held in stock.
Is there a generic Heparin, Combinations in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
2 holders have a Canadian DIN containing Heparin, Combinations, across 8 DINs, of which 4 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| B. BRAUN MEDICAL INC | 4 | 3 | HEPARIN SODIUM 20000UNITS IN 5% DEXTROSE INJ, HEPARIN SODIUM 25000UNITS IN 5% DEXTROSE INJ, HEPARIN SODIUM IN 0.9% SODIUM CHLORIDE INJECTION, HEPARIN SODIUM IN 5% DEXTROSE INJECTION, 25000UNIT/500ML | Sourceable in Canada |
| BAXTER CORPORATION | 4 | 1 | HEPARIN SOD AND 0.9% SOD CHLORIDE INJ, HEPARIN SODIUM & 5% DEXTROSE INJECTION LIQ, HEPARIN SODIUM & DEXTROSE 5% IN VIAFLEX LIQ, HEPARIN SODIUM AND DEXTROSE 5% INJ USP | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 430 MG / 100 ML |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Substance and classification
| Active substance | Heparin, Combinations |
|---|---|
| ATC code | B01AB51 |
| AHFS class | 20:12.04.16 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 01935933 |
|---|---|
| DIN (unpadded, as printed on some documents) | 1935933 |
| Brand name | HEPARIN SODIUM IN 0.9% SODIUM CHLORIDE INJECTION |
| Generic / active ingredient | SODIUM PHOSPHATE DIBASIC : 430 MG / 100 ML CITRIC ACID : 37 MG / 100 ML SODIUM CHLORIDE : 900 MG / 100 ML HEPARIN SODIUM : 200 UNIT / 100 ML |
| Market authorization holder | B. BRAUN MEDICAL INC |
| Health Canada schedule | Ethical |
| ATC code | B01AB51 |
| ATC anatomical main group | B — Blood and blood-forming organs |
| ATC therapeutic subgroup | B01AB |
| Current status | DORMANT |
| Status date | 14-Jul-2017 |
| Original market date | 1996-09-10 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
4 of 8 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| HEPARIN SOD AND 0.9% SOD CHLORIDE INJ | 2 UNIT | SOLUTION | BAXTER CORPORATION | MARKETED | 00828750 |
| HEPARIN SODIUM 20000UNITS IN 5% DEXTROSE INJ | 4000 UNIT / 100 ML | SOLUTION | B. BRAUN MEDICAL INC | MARKETED | 02209713 |
| HEPARIN SODIUM 25000UNITS IN 5% DEXTROSE INJ | 5 G / 100 ML | SOLUTION | B. BRAUN MEDICAL INC | MARKETED | 02209721 |
| HEPARIN SODIUM IN 5% DEXTROSE INJECTION, 25000UNIT/500ML | 5 G / 100 ML | SOLUTION | B. BRAUN MEDICAL INC | MARKETED | 01935941 |
| HEPARIN SODIUM & 5% DEXTROSE INJECTION LIQ | 5 G / 100 ML | SOLUTION | BAXTER CORPORATION | CANCELLED POST MARKET | 02008181 |
| HEPARIN SODIUM & DEXTROSE 5% IN VIAFLEX LIQ | 5 G / 100 ML | SOLUTION | BAXTER CORPORATION | CANCELLED POST MARKET | 01900757 |
| HEPARIN SODIUM AND DEXTROSE 5% INJ USP | 5 G / 100 ML | LIQUID | BAXTER CORPORATION | CANCELLED POST MARKET | 01913255 |
2 · Same class — other molecules in ATC B01AB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Enoxaparin | AXBERI · AXBERI HP · ELONOX · ELONOX HP · +9 more | 46 | 44 | Yes |
| Tinzaparin | INNOHEP · INNOHEP DISP.SYR.-11700 ANTI-XA IU/ML · LOGIPARIN LIQ SC 10000 FXAIU/ML | 13 | 11 | Yes |
| Heparin | CALCILEAN INJ 20000UNIT/0.8ML · CALCIPARINE INJ 20000IU/AMP · CALCIPARINE INJ 5000IU · HEPALEAN 10,000 USP · +17 more | 32 | 10 | Yes |
| Dalteparin | FRAGMIN · FRAGMIN INJ.-LIQ 2500 IU(ANTI-XA)/ML | 13 | 10 | Yes |
| Heparin, Combinations | HEPARIN SOD AND 0.9% SOD CHLORIDE INJ · HEPARIN SODIUM & 5% DEXTROSE INJECTION LIQ · HEPARIN SODIUM & DEXTROSE 5% IN VIAFLEX LIQ · HEPARIN SODIUM 20000UNITS IN 5% DEXTROSE INJ · +4 more | 8 | 4 | Yes |
| Antithrombin | ANTITHROMBIN III IMMUNO · ANTITHROMBIN III NF · THROMBATE III · THROMBATE III PWS IV 1000IU/VIAL · +1 more | 7 | 2 | Yes |
| Danaparoid | ORGARAN | 1 | 1 | Yes |
| Nadroparin | FRAXIPARINE · FRAXIPARINE FORTE | 8 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC B01A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| B01AF | Apixaban · Edoxaban · Rivaroxaban | 159 | 121 |
| B01AC | Abciximab · Acetylsalicylic Acid · Cangrelor · Clopidogrel · Combinations · +10 more | 158 | 66 |
| B01AA | Acenocoumarol · Warfarin | 62 | 16 |
| B01AE | Argatroban · Bivalirudin · Dabigatran Etexilate · Lepirudin | 18 | 11 |
| B01AX | Caplacizumab · Defibrotide · Fondaparinux | 10 | 5 |
| B01AD | Alteplase · Ancrod · Anistreplase · Drotrecogin Alfa · Reteplase · +3 more | 22 | 4 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
This DIN is dormant — it holds a Health Canada authorization but is not currently being marketed in Canada, so it cannot simply be ordered from Canadian stock. Where a patient need exists, supply may be possible through exceptional importation or the Special Access Programme, subject to Health Canada's requirements and the prescriber's application. Nexara can advise on the route and on marketed alternatives.
Ask about sourcing HEPARIN SODIUM IN 0.9% SODIUM CHLORIDE INJECTION
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.